On February 18, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported that the company will participate in the upcoming Digital RAS-Targeted Drug Discovery Summit being held February 23-25, 2021 (Press release, Revolution Medicines, FEB 18, 2021, View Source [SID1234575280]). Steve Kelsey, M.D., president, research and development, will be a featured speaker during the virtual event and will provide a scientific update on the company’s first-in-class RAS(ON) Inhibitor programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Revolution Medicines recently announced the entry of two RAS(ON) Inhibitor programs into IND-enabling development: RMC-6291, a potent, oral and selective tri-complex inhibitor of KRASG12C(ON); and RMC-6236 a potent, oral and RAS-selective tri-complex KRASMULTI(ON) inhibitor.

Details of Revolution Medicines’ participation in the RAS-Targeted Drug Development Summit are as follows:

Presentation:

Title: Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations
Presenter: Steve Kelsey, M.D., president, research and development
Date: Thursday, February 25, 2021
Time: 10:30 a.m. Eastern
Panel Discussion:

Title: Mechanisms of Resistance for Combination Therapies
Participant: Steve Kelsey, M.D., president, research and development
Date: Thursday, February 25, 2021
Time: 11:00 a.m. Eastern
Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at View Source

Revolution Medicines also reported that the company will participate in three upcoming investor conferences. Details of these events are as follows:

10th Annual SVB Leerink Global Healthcare Conference
Fireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference date: February 22-26, 2021
Fireside chat time: 1:40 – 2:10 p.m. Eastern on February 25, 2021
Format: Virtual conference; webcast available
41st Annual Cowen Healthcare Conference
Fireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference dates: March 1-4, 2021
Fireside chat time: 10:20 – 10:50 a.m. Eastern on March 3, 2021
Format: Virtual conference; webcast available
HC Wainwright Global Life Science Conference
Corporate presentation delivered by Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference dates: March 9-10, 2021
Presentation time: 7:00 a.m. Eastern on March 9, 2021
Format: Virtual conference; webcast available
To access the live webcasts of the fireside chats and corporate presentation at these investor conferences, please visit the "Events & Presentations" page within the Investors section of Revolution Medicines’ website at View Source Additionally, replays of the webcasts will be available on the "Events & Presentations" page of the Revolution Medicines’ website for at least 14 days following the conference.